---
title: "LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282435088.md"
description: "LIVZON PHARMA announced that its application for JP-1366 tablets has been approved by the National Medical Products Administration to conduct clinical trials in combination with antibiotics to eradicate Helicobacter pylori. JP-1366 tablets are an innovative potassium ion competitive acid blocker, which had previously been applied for the treatment of gastroesophageal reflux disease and was accepted in August 2025; the injectable form for the Phase II clinical trial for bleeding peptic ulcers began in October 2025"
datetime: "2026-04-12T06:01:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282435088.md)
  - [en](https://longbridge.com/en/news/282435088.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282435088.md)
---

# LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approved

LIVZON PHARMA (01513.HK) announced that the JP-1366 tablets it applied for have been approved by the National Medical Products Administration to conduct clinical trials for the indication "to eradicate Helicobacter pylori in combination with appropriate antibiotics."

JP-1366 tablets are an innovative potassium ion competitive acid blocker. Previously, its application for marketing for the treatment of gastroesophageal reflux disease was accepted in August 2025; while the injectable form for the treatment of bleeding peptic ulcers has entered Phase II clinical trials in October 2025

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Shanghai Henlius wins Australia clearance to start Phase 1 HLX3902 cancer trial](https://longbridge.com/en/news/287190785.md)
- [SSY Group wins China NMPA approval for emedastine difumarate eye drops 0.05%](https://longbridge.com/en/news/287187916.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)